Outcomes After Listing for Liver Transplant in Patients With Acute-on-Chronic Liver Failure: The Multicenter North American Consortium for the Study of End-Stage Liver Disease Experience.


Journal

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
ISSN: 1527-6473
Titre abrégé: Liver Transpl
Pays: United States
ID NLM: 100909185

Informations de publication

Date de publication:
04 2019
Historique:
received: 15 09 2018
accepted: 08 01 2019
pubmed: 7 2 2019
medline: 6 5 2020
entrez: 7 2 2019
Statut: ppublish

Résumé

Acute-on-chronic liver failure (ACLF) characterized with ≥2 extrahepatic organ failures in cirrhosis carries a high mortality. Outcomes of patients listed for liver transplantation (LT) after ACLF and after LT are largely unknown. The North American Consortium for the Study of End-Stage Liver Disease prospectively enrolled 2793 nonelectively hospitalized patients with cirrhosis; 768 were listed for LT. Within 3 months, 265 (35%) received a LT, 395 remained alive without LT, and 108 died/delisted. Compared with nonlisted patients, those listed were younger and more often had ACLF, acute kidney injury, and a higher admission Model for End-Stage Liver Disease (MELD) score. ACLF was most common in patients who died/delisted, followed by those alive with and without LT respectively, (30%, 22%, and 7%, respectively; P < 0.001). At LT, median MELD was 27.9% and 70% were inpatients; median time from hospitalization to LT was 26 days. Post-LT survival at 6 months was unchanged between those with and without ACLF (93% each at 6 months). There was no difference in 3- and 6-month mean post-LT creatinine in those with and without ACLF, despite those with ACLF having a higher mean pre-LT creatinine and a higher rate of perioperative dialysis (61%). In conclusion, patients with and without ACLF had similar survival after transplant with excellent renal recovery in both groups.

Identifiants

pubmed: 30724010
doi: 10.1002/lt.25426
doi:

Types de publication

Comparative Study Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

571-579

Informations de copyright

Copyright © 2019 by the American Association for the Study of Liver Diseases.

Auteurs

Jacqueline G O'Leary (JG)

Dallas VA Medical Center, Dallas, TX.
Baylor University Medical Center, Dallas, TX.

Jasmohan S Bajaj (JS)

Medicine, Virginia Commonwealth University and McGuire VA Medical Center, Richmond, VA.

Puneeta Tandon (P)

University of Alberta, Edmonton, Alberta, Canada.

Scott W Biggins (SW)

University of Washington, Seattle, WA.

Florence Wong (F)

University of Toronto, Toronto, Ontario, Canada.

Patrick S Kamath (PS)

Mayo Clinic, Rochester, MN.

Guadalupe Garcia-Tsao (G)

Yale University, New Haven, CT.

Benedict Maliakkal (B)

University of Rochester, Rochester, NY.

Jennifer Lai (J)

University of California, San Francisco, CA.

Michael Fallon (M)

University of Texas, Health Science Center, Houston, TX.

Hugo E Vargas (HE)

Mayo Clinic, Scottsdale, AZ.

Paul Thuluvath (P)

Mercy Medical Center, University of Maryland School of Medicine, Baltimore, MD.

Ram Subramanian (R)

Emory University, Atlanta, GA.

Leroy R Thacker (LR)

Biostatistics, Richmond, VA.

K Rajender Reddy (KR)

University of Pennsylvania, Philadelphia, PA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH